Clinical Trials Logo

Bipolar Disorder clinical trials

View clinical trials related to Bipolar Disorder.

Filter by:

NCT ID: NCT00224822 Completed - Schizophrenia Clinical Trials

The Effects of Aripiprazole on Patients With Metabolic Syndrome

Start date: March 2004
Phase: Phase 4
Study type: Interventional

The primary goal of this study is to assess the effect of aripiprazole on patients who developed metabolic syndrome while taking other second generation antipsychotic medications.

NCT ID: NCT00224510 Completed - Bipolar Disorder Clinical Trials

A Study To Investigate The Antidepressant Effect Of Lamotrigine In Patients With Bipolar Disorder Using Lithium

Start date: August 2002
Phase: Phase 3
Study type: Interventional

This is a study that, in the first 16 weeks, investigates whether lamotrigine versus placebo offers effect on depressive episodes for patients with bipolar disorder (also known as manic depressive disorder) who use lithium. In the following 50 weeks it is investigated whether these patients experience effect on their depressive and/ or (hypo)manic episodes.

NCT ID: NCT00224380 Completed - Depression Clinical Trials

Medication Adherence in Older Adults With Serious Mental Illness

Start date: July 2003
Phase: N/A
Study type: Interventional

The goal of this pilot study is to learn about how well older people with serious mental illness (including schizophrenia, schizoaffective disorder, bipolar disorder, major depression) follow prescribed medication regimens, and to evaluate a manualized intervention designed to enhance medication management skills and adherence, the Using Medications Effectively program. The following four hypotheses will be tested: 1. Medication adherence will be associated with several variables including insight, memory, medication management skill, knowledge about medications, attitudes about medications. 2. People who receive the program will have better medication adherence compared to those who do not receive the program as measured by pill counts. 3. People who receive the program will develop better medication management skills compared to those who do not receive the program.

NCT ID: NCT00224276 Completed - Schizophrenia Clinical Trials

Prevalence of Diabetes Mellitus Among Patients Treated With Atypical and Conventional Antipsychotics

Start date: n/a
Phase: Phase 4
Study type: Observational

This pilot study hypothesizes that diagnosed and undiagnosed prevalence of diabetes mellitus may differ across antipsychotioc medications in a community mental health center. The study further hypothesizes that control of diabetes among diagnosed cases may be suboptimal.

NCT ID: NCT00223509 Completed - Bipolar Disorder Clinical Trials

Lamictal As Add on Treatment in Mixed States of Bipolar Disorder

Start date: August 2005
Phase: Phase 4
Study type: Interventional

- To evaluate the efficacy and safety of LAM+existing regimen of mood stabilizer in the acute treatment of patients in a mixed state of bipolar disorder. - To evaluate the efficacy and of a combination of LAM+existing regimen of mood stabilizers in the maintenance treatment of patients with mixed state of bipolar disorder

NCT ID: NCT00223496 Completed - Bipolar Disorder Clinical Trials

12- Week Open Label Treatment of Refractory Bipolar Depression

Start date: September 2004
Phase: Phase 4
Study type: Interventional

1. Determine the change in symptomatology and function in refractory bipolar depression, when treated with combination of DEP+AZP for a period of 12 weeks 2. Determine the tolerability and safety of AZP added to DEP in the treatment of refractory bipolar depression

NCT ID: NCT00223275 Completed - Bipolar Disorder Clinical Trials

Naltrexone for Bipolar Disorder and Alcohol Dependence

Start date: May 2005
Phase: Phase 4
Study type: Interventional

The abuse of alcohol is especially common in people with bipolar disorder. However, very little is known about how to treat people with both bipolar disorder and alcohol abuse/dependence. The purpose of this research is to determine whether naltrexone add-on therapy is associated with a greater reduction in alcohol use and alcohol craving than with placebo (an inactive substance) therapy.

NCT ID: NCT00223249 Completed - Bipolar Disorder Clinical Trials

Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence

Start date: November 2002
Phase: Phase 4
Study type: Interventional

The abuse of alcohol is especially common in people with bipolar disorder. However, very little is known about the pharmacotherapy of people with both bipolar disorder and alcohol abuse/dependence. The purpose of this study is to determine if alcohol use and cravings are decreased with quetiapine add-on therapy compared to placebo and to determine if quetiapine add-on therapy is associated with greater improvement in mood, impulsivity, functioning and decreased alcohol use than placebo.

NCT ID: NCT00223210 Completed - Bipolar Disorder Clinical Trials

An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence

Start date: November 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if quetiapine add-on therapy is associated with a decrease in cocaine use and craving and a greater improvement in mood.

NCT ID: NCT00223197 Completed - Clinical trials for Major Depressive Disorder

Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse

Start date: February 2004
Phase: Phase 4
Study type: Interventional

The purpose of this research is to determine if pregnenolone supplement is associated with a reduction in substance use and craving in patients with recurrent major depressive disorder or bipolar disorder and substance abuse/dependence. This research also wants to explore if pregnenolone supplements are associated with improvement in psychiatric symptoms and memory, which are often negatively affected in these patients. It is hypothesized that patients receiving pregnenolone supplements would show greater improvements in mood symptoms and memory, and crave substances less than the patients receiving placebo.